dapagliflozin + sitagliptin + metformin

This is an oral **fixed-dose combination drug** containing dapagliflozin (an SGLT2 inhibitor), sitagliptin (a DPP-4 inhibitor), and metformin (a biguanide), used for treatment of **type 2 diabetes mellitus** in adults, especially those inadequately controlled with metformin alone[1][3].\n- **Dapagliflozin** inhibits sodium-glucose co-transporter 2 in the kidney, increasing urinary glucose excretion and lowering plasma glucose.\n- **Sitagliptin** inhibits dipeptidyl peptidase 4, increases incretin levels, enhances insulin secretion in response to meals, and reduces hepatic glucose production.\n- **Metformin** decreases hepatic glucose output, decreases absorption of glucose from the GI tract, and improves insulin sensitivity in peripheral tissues.\nThis triple combination allows for **complementary mechanisms**, leading to improved glycemic control with low risk of hypoglycemia and minimal weight gain[1][3]. It is primarily indicated as adjunct to diet and exercise for patients with type 2 diabetes not adequately controlled with dual or monotherapy[1][3].\nMultiple brands in India and elsewhere manufacture this specific triple combination as a single extended-release tablet[1][3].

Brand names

Voage-MSGlipcrin DMSitashine DMElectsita-DMDapcard SMSitadapa MSitaviron DMZeusit TrioJemonda-S

Other names

dapagliflozin + sitagliptin + metformin